Biblio

Eekers D, Roelofs E, Cubillos-Mesias M, et al. Data from: Intensity-modulated proton therapy decreases dose to organs at risk in low-grade glioma patients: results of a multicentric in silico ROCOCO trial. 2018. doi:10.17195/candat.2018.05.1.

• DOI
• Google Scholar

CanDat - 2018 Eekers - Data LGG .ods (157.14 KB) CanDat - 2018 Eekers - Data LGG .xlsx (183.07 KB)

Eekers DBP, Ven Lin 't, Deprez S, et al. The posterior cerebellum, a new organ at risk?. Clinical and Translational Radiation Oncology. 2018;8:22 - 26. doi:10.1016/j.ctro.2017.11.010.

• DOI
• Google Scholar

Jochems A, Deist TM, Naqa IEl, et al. Data from: Developing and validating a survival prediction model for NSCLC patients through distributed learning across three countries. 2017. doi:10.17195/candat.2017.02.2.

• DOI
• Google Scholar

Jochems-2017-MaastroDataUnbinned.csv (62.76 KB)

van Timmeren J, Leijenaar RTH, van Elmpt W, et al. Data from: Survival prediction of non-small cell lung cancer patients using radiomics analyses of cone-beam CT images. 2017. doi:10.17195/candat.2017.02.1.

• DOI
• Google Scholar

Van-Timmeren_2017_cases-001-020.zip (750.99 MB) Van-Timmeren_2017_cases-021-040.zip (726.98 MB) Van-Timmeren_2017_cases-041-060.zip (777.6 MB) Van-Timmeren_2017_cases-061-080.zip (795.72 MB) Van-Timmeren_2017_cases-081-102.zip (827.01 MB)

Jochems A, Deist TM, Naqa IEl, et al. Developing and Validating a Survival Prediction Model for NSCLC Patients Through Distributed Learning Across 3 Countries. International Journal of Radiation Oncology*Biology*Physics. 2017;99(2):344 - 352. doi:10.1016/j.ijrobp.2017.04.021.

• DOI
• Google Scholar

Eekers D, Roelofs E, Jelen U, et al. Data from: Benefit of particle therapy in re-irradiation of head and neck patients. Results of a multicenter in silico ROCOCO trial. 2016. doi:10.17195/candat.2016.04.2.

• DOI
• Google Scholar

Even A, Hamming-Vrieze O, van Elmpt W, et al. Data from: Quantitative assessment of Zirconium-89 labeled cetuximab using PETCT imaging in patients with advanced head and neck cancer - a theragnostic approach. 2016. doi:10.17195/candat.2016.11.1.

• DOI
• Google Scholar

Even_P0037C0006I4475579.ZIP (97.26 MB) Even_P0037C0006I5879176.ZIP (131.21 MB) Even_P0037C0006I6042760.ZIP (115.71 MB) Even_P0037C0006I8991415.ZIP (101.03 MB)

Even A, Hamming-Vrieze O, van Elmpt W, et al. Data from: Quantitative assessment of Zirconium-89 labeled cetuximab using PETCT imaging in patients with advanced head and neck cancer - a theragnostic approach. 2016. doi:10.17195/candat.2016.11.1.

• DOI
• Google Scholar

Even_P0037C0006I4475579.ZIP (97.26 MB) Even_P0037C0006I5879176.ZIP (131.21 MB) Even_P0037C0006I6042760.ZIP (115.71 MB) Even_P0037C0006I8991415.ZIP (101.03 MB)

Even A, Hamming-Vrieze O, van Elmpt W, et al. Data from: Quantitative assessment of Zirconium-89 labeled cetuximab using PETCT imaging in patients with advanced head and neck cancer - a theragnostic approach. 2016. doi:10.17195/candat.2016.11.1.

• DOI
• Google Scholar

Even_P0037C0006I4475579.ZIP (97.26 MB) Even_P0037C0006I5879176.ZIP (131.21 MB) Even_P0037C0006I6042760.ZIP (115.71 MB) Even_P0037C0006I8991415.ZIP (101.03 MB)

Even A, Hamming-Vrieze O, van Elmpt W, et al. Data from: Quantitative assessment of Zirconium-89 labeled cetuximab using PETCT imaging in patients with advanced head and neck cancer - a theragnostic approach. 2016. doi:10.17195/candat.2016.11.1.

• DOI
• Google Scholar

Even_P0037C0006I4475579.ZIP (97.26 MB) Even_P0037C0006I5879176.ZIP (131.21 MB) Even_P0037C0006I6042760.ZIP (115.71 MB) Even_P0037C0006I8991415.ZIP (101.03 MB)

Cheng Q, Roelofs E, Ramaekers B, et al. Data from: Development and Evaluation of an Online Three-Level Proton vs Photon Decision Support Prototype for Head and Neck Cancer - Comparison of Dose, Toxicity and Cost-Effectiveness. 2015. doi:10.17195/candat.2015.10.5.

• DOI
• Google Scholar

PRODECIS-HNC-results.xlsx (43.25 KB) PRODECIS-HNC-Figure-2.png (47.07 KB)

Oberije C, De Ruysscher D, Houben R, et al. A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients. Int J Radiat Oncol Biol Phys. 2015;92(4):935-44. doi:10.1016/j.ijrobp.2015.02.048.

• PubMed
• DOI
• Google Scholar

Aerts HJWL, Velazquez ERios, Leijenaar RTH, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006. doi:10.1038/ncomms5006.

• PubMed
• DOI
• Google Scholar

Aerts HJWL, Velazquez ERios, Leijenaar RTH, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006. doi:10.1038/ncomms5006.

• PubMed
• DOI
• Google Scholar

Velazquez ERios, Hoebers F, Aerts HJWL, et al. Externally validated HPV-based prognostic nomogram for oropharyngeal carcinoma patients yields more accurate predictions than TNM staging. Radiother Oncol. 2014;113(3):324-30. doi:10.1016/j.radonc.2014.09.005.

• PubMed
• DOI
• Google Scholar

Starmans MHW, Chu KC, Haider S, et al. The prognostic value of temporal in vitro and in vivo derived hypoxia gene-expression signatures in breast cancer. Radiotherapy and Oncology. 2012;102(3):436 - 443. doi:10.1016/j.radonc.2012.02.002.

• DOI
• Google Scholar

Loon J, Janssen MHM, Oellers MC, et al. PET imaging of hypoxia using [18F]HX4: a phase I trial. European Journal of Nuclear Medicine and Molecular Imaging. 2010;37(9):1663 - 1668. doi:10.1007/s00259-010-1437-x.

• DOI
• Google Scholar